A deal has been reached between AbbVie Inc. and Boehringer Ingelheim, with the latter agreeing not to launch its biosimilar version of Humira® until July 1, 2023. Under the settlement agreement, Boehringer will receive a non-exclusive license for Humira®'s patents, with AbbVie stating it will make no payments of any form to Boehringer. Earning $20 billion globally in 2018, Humira®, or adalimumab, is the world's top-selling drug and treats rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis and plaque psoriasis, among other conditions.
Award/Ranking
Managing IP Americas Awards 2024: Finnegan Shortlisted for Nine Awards, Including Firm of the Year
March 12, 2024
Commentary
February 29, 2024
Press Release
Finnegan Secures Another Patent Victory for BMW Group in the District of Delaware
February 27, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.